Thomas C. Freyman, former executive vice president of finance and administration at Abbott Laboratories, has joined Allergan’s Board of Directors. He brings nearly 40 years of healthcare industry and finance experience to the role.
“Since Allergan transitioned from a generics company to a branded biopharmaceutical company, the Allergan Board has been actively involved in a refreshment process to update its membership with the appropriate experience, talent and diversity to more strongly position Allergan as a premier biopharmaceutical company and create value for shareholders,” said Chris Coughlin, lead independent director. “Mr. Freyman will become the fourth new director joining the Allergan Board in 16 months as we continue to recruit highly experienced and qualified members to bring a diversity of perspectives and strengthen the board with additional industry, scientific and financial experience.”
Allergan also announced that director Patrick O’Sullivan will retire from the board in July. O’Sullivan joined the Allergan board in October 2013 following the company’s acquisition of Warner Chilcott, having served as a member of the Warner Chilcott Board from 2009. Following his retirement the board will continue to have 12 members of which 10 are independent.